AI-driven de novo drug discovery platform delivers novel, potency-ranked, safety-filtered and synthesizable drug candidates conditioned on the protein target. The de novo molecule generator is constrained and guided by an evaluator trained on real experimental bioactivity data.
Protein target identification from a context-aware knowledge graph, built for the disease of interest.